Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piboserod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 17/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.78 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.78 |
| ▸ | HRH2 | P25021 | 1/20 | 0.78 |
| ▸ | HTR1D | P28221 | 1/20 | 0.78 |
| ▸ | HTR2A | P28223 | 1/20 | 0.78 |
| ▸ | HRH1 | P35367 | 1/20 | 0.78 |
| ▸ | HTR2B | P41595 | 1/20 | 0.78 |
| ▸ | HTR3A | P46098 | 1/20 | 0.78 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piboserod SCHEMBL30234609 | 1.00 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| Piboserod SCHEMBL2228911 | 0.99 | HTR4 (0.98) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7333331 | 0.91 | HTR4 (0.82) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL8286732 | 0.90 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7365338 | 0.90 | HTR4 (0.82) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL6909544 | 0.89 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL8287824 | 0.89 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL8423110 | 0.88 | HTR4 (0.79) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL8287825 | 0.88 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7367850 | 0.88 | HTR4 (0.82) | HTR4CHRM2ADRA2BHRH2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4017486-A1 | COMPOSITONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND USES THEREOF | Buzzelet Development And Technologies Ltd (IL) | 2022-06-29 | — | — | EP | claimed |
| US-20220168246-A1 | COMPOSITONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND USES THEREOF | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) | 2022-06-02 | — | — | US | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2021116487-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF NIEMANN-PICK C DISEASE | SOM INNOVATION BIOTECH, S.A. (ES) | 2021-06-17 | — | — | WO | claimed |
| WO-2021033149-A1 | COMPOSITONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND USES THEREOF | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD. (IL) | 2021-02-25 | — | — | WO | claimed |
| WO-2020210643-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2020-10-15 | — | — | WO | claimed |
| US-20190030039-A1 | PREVENTION OF SSRI-INDUCED GASTROINTESTINAL DYSFUNCTION WITH A 5-HT4 RECEPTOR ANTAGONIST | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-01-31 | — | — | US | claimed |
| WO-2017127721-A1 | PREVENTION OF SSRI-INDUCED GASTROINTESTINAL DYSFUNCTION WITH A 5-HT4 RECEPTOR ANTAGONIST | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-07-27 | — | — | WO | claimed |
| EP-0927163-B1 | PREPARATION OF 1-BUTYL-4-PIPERIDINYLMETHYLAMINE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-28 | — | — | EP | claimed |
| US-20060241134-A1 | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility | ALTANA PHARMA GA (DE) | 2006-10-26 | — | — | US | claimed |
| EP-1644043-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA Pharma AG (DE) | 2006-04-12 | — | — | EP | claimed |
| US-20060057218-A1 | N-[1-butyl-4-piperidinylmethyl[3,4-dihydro-2 oxazino[3,2-a indole-10 carboxamide as drugs with Cahpo4 or Ca3/po4/2 fillers or binders for use in treatment of irritable bowel syndrome, urinry incontience or arrhythmias | SMITHKLINE BEECHAM P.L.C. | 2006-03-16 | — | — | US | claimed |
| WO-2005074931-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING (S) -PANTOPRAZOLE | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | claimed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | claimed |
| EP-1097136-B1 | PROCESS FOR THE PREPARATION OF AN INDOLE DERIVATIVE | SMITHKLINE BEECHAM PLC (GB) | 2003-10-22 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20030032640-A1 | Novel composition | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-02-13 | — | — | US | claimed |
| US-6100397-A | Process for the preparation of N-[(1-n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a] indole-10-carboxamide and salts and intermediates in the process | SMITHKLINE BEECHAM PLC (GB) | 2000-08-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060057218-A1 | N-[1-butyl-4-piperidinylmethyl[3,4-dihydro-2 oxazino[3,2-a indole-10 carboxamide as drugs with Cahpo4 or Ca3/po4/2 fillers or binders for use in treatment of irritable bowel syndrome, urinry incontience or arrhythmias | IDO1, CACNA1E, KCNN4 | HTR4 59/4885CHRM2 595/4885ADRA2B 831/4885 |
| US-20030032640-A1 | Novel composition | PLOD3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, BRD3 | HTR4 344/4885CHRM2 514/4885ADRA2B 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.